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Abstract
Background: The mutation of the IRS-1 gene is one of the genetic risk factors which, it is speculated, is associated with insulin resistance
or predisposition to type 2 diabetes. The aim of our study was to evaluate the association between the Gly972Arg polymorphism in the
IRS-1 gene and birth weight in newborn children with adequate gestational age.
Material and methods: 100 newborn children with adequate gestational age (38–42 weeks), whose mother had no disorders during
pregnancy, were studied. Genomic DNA was extracted from umbilical cord blood leukocytes, and Gly972Arg polymorphism in the IRS-1
gene was genotyped using the PCR-based method.
Results: Birth weight was significantly lower in the newborn with the IRS-1 Gly972Arg polymorphism compared with a control group
(3161.75 ± 380.86 g vs. 3427.92 ± 468.86 g). Body length and head circumference at birth were also lower in the neonates with that polymor-
phism (54.38 ± 3.13 cm vs. 52.69 ± 2.91 cm, and 34.08 ± 1.47 vs. 33.63 ± 0.81, respectively).
Conclusions: The results suggest that the Gly972Arg genotype is associated with lower birth weight, body length and head circumference
in neonates with adequate gestational age.  (Pol J Endocrinol 2008; 59 (3): 212–216)
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Streszczenie
Wstęp: Mutacja genu substratu 1 receptora insuliny (IRS-1, insulin receptor substrate-1) jest jednym z genetycznych czynników ryzyka,
przypuszczalnie związanych z występowaniem zjawiska oporności na insulinę lub predyspozycją do wystąpienia cukrzycy typu 2.  Ce-
lem niniejszego badania była ocena potencjalnych zależności między polimorfizmem Gly972Arg w genie IRS-1 a masą ciała u noworod-
ków urodzonych o czasie.
Materiał i metody: W badaniu wzięło udział 100 noworodków urodzonych o czasie (38–42 tydzień ciąży), których matki nie chorowały
podczas ciąży. Po wyekstrahowaniu genomowego DNA z leukocytów krwi pępowinowej przeprowadzono z użyciem metody PCR ocenę
polimorfizmu Gly972Arg genu IR-1.
Wyniki: Urodzeniowa masa ciała była istotnie niższa u noworodków z polimorfizmem Gly972Arg genu IRS-1 w porównaniu z grupą
kontrolną  (3161,75 ± 380,86 g vs. 3427,92 ± 468,86 g). U noworodków z tym polimorfizmem  zaobserwowano również mniejszą długość
ciała oraz mniejszy obwód głowy (odpowiednio: 54,38 ± 3,13 cm vs. 52,69 ± 2,91 cm oraz 34,08 ± 1,47 cm vs. 33,63 ± 0,81 cm).
Wnioski: Wyniki sugerują, że genotyp Gly972Arg u noworodków urodzonych o czasie wiąże się z niższą urodzeniową masą ciała, mniejszą
długością ciała oraz mniejszym obwodem głowy. (Endokrynol Pol 2008; 59 (3): 212–216)
Słowa kluczowe: IRS-1, Gly972Arg, waga urodzeniowa, cukrzyca typu 2
Introduction
In recent years a number of studies have reported
a genetic predisposition to the occurrence of type 2 dia-
betes. It is speculated that the mutation of the IRS-1 gene
is one of the genetic risk- factors associated with insulin
resistance or predisposition to type 2 diabetes [1]. The-
re are around 11 known polymorphisms in the IRS-1
gene, the most common variant being GlyÆ972ÆArg
replacement, which is a result of guanine by adenine
substitution at the DNA chain [2, 3]. This polymorphism
is more prevalent in patients with marked insulin resistan-
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ce, whether this is associated with type 2 diabetes or
not [3, 4]. The Gly972Arg polymorphism in the IRS-1
gene is associated with significant impairment of the
insulin signalling pathway and may induce abnormali-
ties in the functioning of the pancreatic beta-cells, such
as a decrease in insulin secretion, a greater number of
immature secretory granules and/or peripheral insulin
resistance. This has been examined in type 2 diabetic
subjects and controls from various populations, and in
outcomes prevalence was higher in patients with type
2 diabetes than among healthy controls [2–6]. Accor-
ding to the meta-analysis conducted in 2003, carriers of
the Gly972Arg variant of the IRS-1 gene are at 25% in-
creased risk of developing type 2 diabetes compared
with non-carriers. These data suggest that this polymor-
phism represents a risk-factor for type 2 diabetes [7]. In
contrast to this, Florez et al. [8] examined the genoty-
pe-phenotype correlation in three Caucasian samples
of a total of 9000 individuals in order to evaluate the re-
producibility of the model for the meta-analysis establi-
shed by Jellema et al [7]. In their study Gly972Arg poly-
morphism was not associated with type 2 diabetes [8].
Since IRS-1 function is also related to stimulation of
the IGF-1 receptor, the IRS-1 gene polymorphism mi-
ght also influence IGF-1 receptor function. A reduction
in IGF-1 insulin signalling pathway and also in insulin
secretion may contribute to lower birth weight [9, 10].
Material and methods
 The purpose of this study was to determine whether
the Gly972Arg variant of the IRS-1 gene is associated
with decreased birth weight. We studied 100 newborn
children with adequate gestational age (38–42 weeks),
delivered after uncomplicated pregnancies (mothers
had no documented gestational diabetes, type 2 diabe-
tes, impaired glucose tolerance, hypertension, were not
cigarette smokers and were not obese before pregnan-
cy (BMI < 30 kg/m2). The gender of the neonates, birth
weight, body length and head circumference were ta-
ken from standard hospital records after delivery. Ge-
nomic DNA was extracted from umbilical cord blood
leukocytes by standard techniques. The Gly972Arg ge-
notype was obtained by the PCR-Restriction Fragment
Length Polymorphism (RFLP). The product of amplifi-
cation was digested with restriction enzyme Eco881,
recognising the 5’CZ(C/T)CG(A/G)G 3’ sequence. Am-
plified fragments of the IRS-1 gene (homozygote GG
genotype: 169 bp and 29 bp fragments, homozygote AA:
198 bp, and heterozygote GA: 198 bp, 169 bp and 29 bp)
were run on 4% agarose gel and visualised under ultra-
violet illumination. DNA molecular weight marker XIII
(Roche) was used as a DNA reference standard. Writ-
ten informed consent was obtained from the pregnant
mothers, and the study was approved by the Ethics
Committee of the Silesian School of Medicine in Kato-
wice, Poland.
In statistical analysis the multivariant analysis, which
included Gly972Arg polymorphism and demographic
parameters of the mothers (age, gestational age, height
and weight before pregnancy), was performed in or-
der to determine the independent impact of the poly-
morphism examined. All data are presented as means
± standard deviation (SD). P values less than 0.05 were
considered significant. The neonates were divided into
three groups on the basis of IRS-1 genotype: 1 — ho-
mozygote GG, 2 — homozygote AA, 3 — heterozygote
GA. The U test and c² test were used for assessing diffe-
rences between groups.
Results
Table 1 presents the main characteristics of the study
population. Genotype frequencies were: GG — 84%,
GA — 15%, AA — 1%, and distribution was within the
Hardy-Weinberg equilibrium. Birth weight was signifi-
cantly lower in the newborn carrying the IRS-1
Gly972Arg variant than in non-carriers. Body length and
head circumference at birth were also lower in the neo-
nates carrying the Gly972Arg variant (Table 1). Mothers
whose children were carriers of the Gly972Arg variant
were found to have had lower body weight (57.69 ±
± 7.43 kg) than mothers in the control group (60.19 ±
± 10.24 kg), whose children were not carriers of the po-
lymorphism. The difference was borderline significant
(p = 0.06) (Table I).
There were no significant differences between the
groups with regard to the gestational age of the neona-
tes, the age of the mothers or their height and BMI. The
multifactorial analysis showed that there was a signifi-
cant independent influence of the examined polymor-
phism on birth weight (p < 0.05).
Discussion
The results of the present study suggest that the
Gly972Arg polymorphism in the IRS-1 gene leads to
decreased birth weight, body length and head circum-
ference in children born at adequate gestational age.
The occurrence of this polymorphism is a significant
independent risk factor for lower birth body weight.
The IRS-1 represents the main candidate potentially
impairing insulin signalling [11, 12]. In vitro studies have
shown that this variant has been associated with decreased
insulin secretion, reduced insulin sensitivity of the periphe-
ral tissues and increased beta-cells apoptosis [11–14]. Mo-
reover, similar abnormalities have been observed in in
vivo settings [6] but were not entirely reproducible [2, 5,
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15–22]. Stumvoll et al. have investigated the association
between insulin secretion in well-matched normal glu-
cose-tolerant patients and the IRS-1 gene marker and
found decreased glucose-stimulated insulin secretion
during the Oral Glucose Tolerance Test (OGTT) during
hyperglycaemic clamp and after maximal stimulation
with arginine. These data suggest that the Gly972Arg
polymorphism in the IRS-1 gene might be associated
with decreased insulin secretion in response to glucose
but not directly with insulin sensitivity [21].
The impact of the Gly972Arg polymorphism in the
IRS-1 gene on insulin action in diabetic patients was
discovered in 1994 [20]. Laakso et al. reported that this
polymorphism could cause impairment of insulin si-
gnalling, insulin resistance and reduction in insulin se-
cretion in subjects with and without diabetes; such
a relationship was confirmed in subsequent studies [11,
23]. Subjects carrying this IRS-1 gene variant had lower
fasting C-peptide concentrations compared to control
groups [16, 24]. They also expressed decreased basic and
insulin-stimulated glucose transport due to a defect in
the translocation of the glucose transporters GLUT-1
and GLUT-4 to the plasma membrane [13].
The carriers of the Gly972Arg IRS-1 polymorphism
presented features of metabolic syndrome: hypergly-
caemia, insulin resistance, increased triglyceride and
free fatty acid levels, microalbuminuria, hypertension
and an increase in intima-media thickness. It can be
suspected, that the IRS-1 gene marker represents a risk
factor of atherosclerosis and cardiovascular disease [25].
The presence of the Gly972Arg polymorphism in
patients with type 2 diabetes was also evaluated in the
United Kingdom Prospective Diabetes Study (UKPDS)
study, but there was no observed increase in the preva-
lence of type 2 diabetes among carriers. It was noted,
however, that the Gly972Arg variant was more common
among subjects with diabetes and profound insulin resi-
stance [6]. On the other hand, according to Florez et al.
there was no association between the Gly972Arg va-
riant and type 2 diabetes in populations of European
descent [26].
The influence of the polymorphism described on the
development of diabetes depends on numerous factors
such as body mass [15, 16], phenotype of disease [7] and
ethnicity, type 2 diabetes occurring more frequently in
the Caucasian population than others [14].
Recent studies present the relationship between lo-
wer birth weight and increased risk of impaired gluco-
se tolerance and diabetes in adults [27–30]. One study,
that by Hales et al., suggests that this is a result of “me-
tabolic programming” during intrauterine growth, or
changes in the gene expression associated with an unfa-
vourable intrauterine environment [31]. Such early ada-
ptations to a nutritional environment could cause me-
tabolism disturbances in later life.
The Gly972Arg polymorphism may thus have led
to a change in the physiology of fuel metabolism and
a decrease in insulin secretion and peripheral insulin
resistance. In the present study we analysed the rela-
tionship between the Gly972Arg genotype, body length
at birth and head circumference. A reduction in birth
weight may be associated with insulin resistance resul-
ting from genetic defects that influence insulin action
during embryogenesis.
The importance of IRS-1 has been demonstrated in
the IRS-1 knockout mice. IRS-1 deficiency mice showed
impaired glucose tolerance, a decrease in insulin-stimula-
ted glucose uptake and a 50% reduction in intrauterine
Table I. IRS-1 gene polymorphism and demographic characteristics of the study groups
Tabela I. Polimorfizm genu IRS-1 a demograficzna charakterystyka badanych grup
  Homozygote GG Homozygote AA and heterozygote GA  p
n 84 16  
Mother’s age at delivery 27.06 ± 4.81* 26.63 ± 4.11 p = 0.18
Mother’s weight
before pregnancy [kg] 60.19 ± 10.24 57.69 ± 7.43 p = 0.06
Mother’s body length [m] 1.66 ± 0.06 1.65 ± 0.07 p = 0.15
Mother’s BMI 21.88 ± 3.51 21.27 ± 2.89 p = 0.11
Gestation weeks 39.15 ± 0.88 38.94 ± 0.85 p = 0.09
Number of gestation 1.85 ± 0.99 2.44 ± 2.73 P = 0.90
Sex of neonate (%) 54/46 69/31 p = 0.94
Birth weight [g] 3427.92 ± 468.86 3161.75 ± 380.86 p = 0.0034
Birth height [cm] 54.38 ± 3.13 52.69 ± 2.91 p = 0.01
Head circumference [cm] 34.08 ± 1.47 33.63 ± 0.81 p = 0.02
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growth [32]. A lack of the IRS-1 gene and glucokinase
gene both lead to reduced birth weight and body size.
Transgenic mice also exhibited resistance to the meta-
bolic effects of insulin in skeletal muscle and adipose
tissue [33]. A mutation in the glucokinase gene does
seems to reduce birth weight and to cause hyperglyca-
emia after birth, perhaps because of decreased secre-
tion in response to maternal glucose levels.
In 1992, Hales et al. hypothesised that lower birth
weight predisposes to the development of diabetes in
later life. The diabetes could result from the incorrect
development of organs during intrauterine life and their
subsequent dysfunction in the adult. It was suggested
in this study that type 2 diabetes is mainly the result of
intrauterine environmental factors, where only a mi-
nor role should be attributed to genetic factors [31].
However, it is now widely accepted that both genetic
and environmental factors are engaged in the pathoge-
nesis of type 2 diabetes. It is also postulated that the same
genetic factors which cause impairment in insulin secre-
tion or lead to insulin resistance might change intraute-
rine growth and glucose tolerance in later life [34].
Recently studies by Mason in the United Kingdom
[35] and by Rasmussen in Denmark [36] found no dif-
ferences in body weight at birth between carriers of the
Gly972Arg variant and a control group, whereas a stu-
dy in Brazil of neonates showed that body size at birth
was lower in a group of Gly972Arg carriers than in
a control group [37].
Conclusion
Our findings seem to suggest an independent associa-
tion of the Gly972Arg genotype in the IRS-1 gene with
decreased intrauterine growth. The results were arrived
at through the applications of statistical analysis alone.
They should be treated as preliminary research and need
to be corroborated by clinical findings in the future.
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